EUVIMEDEUVIMED entdecken
Crossref

Codelivery of Bortezomib and Modified DR5-Selective TRAIL via Amphiphilic Poly( N -vinylpyrrolidone) Bionanocomposites to Overcome Glioblastoma Resistance

Ekaterina V Kukovyakina, Pavel P Kulikov iD, Dmitry V Bagrov iD, Andrey V Moiseenko, Tatiana S Trifonova, Alina A Isakova, Margarita L Shuvalova, Elena V Svirshchevskaya, Irina I Khan, Vadim S Pokrovsky, Marine E Gasparian, Andrey N Kuskov iD und 1 weitere

ACS Applied Bio Materials · 2025

DOI: 10.1021/acsabm.5c01651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2025. Verfasst von Ekaterina V Kukovyakina und 12 weiteren Autor:innen. Beteiligte Einrichtung: D. Mendeleev University of Chemical Technology of Russia, Moscow 125047, Russia. Hauptthemen laut MEDLINE: Bortezomib, Glioblastoma, Antineoplastic Agents, Nanocomposites. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanosized carriers based on amphiphilic poly(N-vinylpyrrolidone) (Amph-PVP) are a versatile delivery system for various therapeutic agents such as anti-inflammatory drugs and plasmid DNA, as well as targeted antitumor drugs and proteins. Earlier, we developed Amph-PVP-based nanoparticles decorated by a modified DR5-specific TRAIL variant DR5-B (PVP-DR5-B) or containing the proteasomal inhibitor bortezomib (PVP-BTZ). Both DR5-B and BTZ have antitumor properties and, when combined, act synergistically on tumor cells. In the present study, Amph-PVP nanoparticles were loaded with BTZ and subsequently decorated with the TRAIL variant DR5-B, producing a dual polymeric bionanocomposite system PVP-BTZ-DR5-B. Using 2D and 3D in vitro cultures of human glioblastoma cell lines U87MG and T98G, it was demonstrated that PVP-BTZ-DR5-B nanoparticles were internalized and accumulated in cells more efficiently, demonstrating significantly enhanced cytotoxicity compared to free DR5-B or PVP-BTZ nanoparticles loaded with bortezomib alone. PVP-BTZ-DR5-B nanoparticles also penetrated the blood-brain barrier more efficiently than DR5-B in an in vitro model. Finally, the enhanced antitumor effect of PVP-BTZ-DR5-B was demonstrated in a xenograft model of U87MG glioblastoma cells in zebrafish embryos in vivo. Thereby, coloading of BTZ and DR5-B into the Amph-PVP nanoparticles is a promising approach to enhance the antitumor efficacy of free drugs and overcome glioblastoma resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibGlioblastomaAntineoplastic AgentsNanocompositesTNF-Related Apoptosis-Inducing LigandBiocompatible MaterialsPovidoneHumansAnimalsZebrafishDrug Resistance, NeoplasmDrug Screening Assays, AntitumorCell Line, TumorParticle SizeMaterials TestingCell SurvivalCell ProliferationDrug CarriersSurface Properties

Stichwörter der Autor:innen

DR5 receptorTRAILamphiphilic poly(N-vinylpyrrolidone) (Amph-PVP)bionanocompositebortezomibglioblastomaself-assembly

Substanzen

BortezomibAntineoplastic AgentsTNF-Related Apoptosis-Inducing LigandBiocompatible MaterialsPovidoneDrug Carriers

Autor:innen und Institutionen

  • D. Mendeleev University of Chemical Technology of Russia, Moscow 125047, Russia.
  • Faculty of Biology, Lomonosov Moscow State University, Moscow 119234, Russia.
  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia.
  • N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115478, Russia.
  • Medical Institute, RUDN University, Moscow 117198, Russia.

ORCID-Profile: Pavel P Kulikov, Dmitry V Bagrov, Andrey N Kuskov, Anne V Yagolovich

Förderung

  • Russian Science Foundation

Zitieren

APA

Kukovyakina, E. V., Kulikov, P. P., Bagrov, D. V., Moiseenko, A. V., Trifonova, T. S., Isakova, A. A., Shuvalova, M. L., Svirshchevskaya, E. V., Khan, I. I., Pokrovsky, V. S., Gasparian, M. E., Kuskov, A. N., & Yagolovich, A. V. (2025). Codelivery of Bortezomib and Modified DR5-Selective TRAIL via Amphiphilic Poly( N -vinylpyrrolidone) Bionanocomposites to Overcome Glioblastoma Resistance. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c01651

Vancouver

Kukovyakina EV, Kulikov PP, Bagrov DV, Moiseenko AV, Trifonova TS, Isakova AA, et al. Codelivery of Bortezomib and Modified DR5-Selective TRAIL via Amphiphilic Poly( N -vinylpyrrolidone) Bionanocomposites to Overcome Glioblastoma Resistance. ACS Applied Bio Materials. 2025. doi:10.1021/acsabm.5c01651

BibTeX
@article{Kukovyakina2025,
  author = {Kukovyakina, Ekaterina V and Kulikov, Pavel P and Bagrov, Dmitry V and Moiseenko, Andrey V and Trifonova, Tatiana S and Isakova, Alina A and Shuvalova, Margarita L and Svirshchevskaya, Elena V and Khan, Irina I and Pokrovsky, Vadim S and Gasparian, Marine E and Kuskov, Andrey N and Yagolovich, Anne V},
  title = {Codelivery of Bortezomib and Modified DR5-Selective TRAIL via Amphiphilic Poly( N -vinylpyrrolidone) Bionanocomposites to Overcome Glioblastoma Resistance},
  journal = {ACS Applied Bio Materials},
  year = {2025},
  doi = {10.1021/acsabm.5c01651}
}
Kostenlos starten →